Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Oct

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?

FDA Approves Combination Regimen for Extensive-Stage SCLC

Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated Advanced NSCLC

In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival

Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk